Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study
Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study
DEERFIELD, Ill. -- JULY 23, 2024-- Walgreens today announced it received a project award valued up to $25 million through the Rapid Response Partnership Vehicle (RRPV) to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection (CoP), known as responses to a vaccine that predict how well a vaccinated person will be protected from future infections, using COVID-19 vaccine data. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS). This partnership underscores a shared commitment to advancing public health through innovative research and leveraging Walgreens' extensive community pharmacies to increase access and representation in clinical trials.
沃爾格林今天宣佈,通過快速響應夥伴關係(RRPV)獲得了價值2500萬美元的項目獎勵,開展第四期觀察性臨床研究,重點評估相關保護(CoP),即對疫苗的反應,預測受疫苗接種的人在未來感染病毒時的保護效果。RRPV是由美國衛生與公共服務部戰略準備和響應管理局(ASPR)下的生物醫學高級研究和開發局(BARDA)資助的聯合體。這種合作關係凸顯了通過創新研究和利用沃爾格林廣泛的社區藥房來增加接觸和參與臨床試驗的共同承諾。
As a leading community pharmacy and front door to the U.S. healthcare system, Walgreens played a pivotal role in the distribution of COVID-19 vaccines and testing throughout the pandemic. Walgreens has administered over 90 million COVID-19 vaccinations to date, showcasing its capacity to handle large-scale health initiatives. Building on this experience, through this collaboration, the BARDA-funded study will utilize select Walgreens community pharmacies as clinical trial sites to assess the effectiveness of FDA-authorized COVID-19 vaccines. This initiative aims to enhance access to clinical research across diverse patient populations, particularly in communities historically underrepresented in clinical trials.
作爲美國領先的社區藥房和通往健康醫療系統的大門,沃爾格林在整個大流行期間發揮了關鍵作用,分發COVID-19疫苗和測試。沃爾格林迄今爲止已經進行了9000萬次COVID-19疫苗接種,展示了處理大規模衛生計劃的能力。通過此次合作,BARDA資助的研究將利用選擇的沃爾格林社區藥房作爲臨床試驗地點,評估FDA授權的COVID-19疫苗的有效性。這個計劃旨在加強跨多樣化患者人口的臨床研究訪問,特別是在歷史上參與臨床試驗較少的社區。
"We are honored to be selected by BARDA and its RRPV for this important study as this is a step forward to utilize public and private partnerships to bring clinical trials into more communities across the country," said Ramita Tandon, chief clinical trials officer at Walgreens. "With our experience in immunizations and trusted relationship with millions of patients and customers, Walgreens is uniquely positioned to support this critical research. As the only retail pharmacy with a national decentralized clinical trial infrastructure and dedicated clinical research staff, we are committed to helping enhance public health preparedness."
“我們很榮幸被BARDA及其RRPV選中參加這項重要研究,這是利用公共和私營合作推廣臨床試驗,把更多的臨床試驗引入更多社區的一大步,”沃爾格林首席臨床試驗官拉米塔·坦頓說。“憑藉我們在免疫接種方面的經驗和與數百萬患者和客戶的信任關係,沃爾格林有獨特的地位來支持這項關鍵研究。作爲唯一一個擁有全國分散式臨床試驗基礎設施和專門的臨床研究人員隊伍的零售藥店,我們致力於幫助提高公共健康準備水平。”
Walgreens will employ a comprehensive approach to participant recruitment, which will leverage its physical footprint in addition to its compliant and secure decentralized clinical trial platform to reach patients where it's most convenient for them. The study will enroll up to 4,000 participants across 20 retail pharmacy locations nationwide, ensuring a diverse and representative study population.
沃爾格林將採用全面的參與者招募方法,利用其物理佔地面積以及符合規定和安全的分散式臨床試驗平台,以最爲方便的方式接觸到患者。該研究將在全國20個零售藥店地點招募最多4,000名參與者,確保招募到多樣化和代表性的研究人群。
Funding for this award was received under Project NextGen, a $5 billion initiative by HHS to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection for COVID-19 than the first-generation COVID vaccines and medicines. BARDA is supporting the development of new vaccines, therapeutics, and enabling technologies to better address the waning immunity and resistance to current and future SARS-CoV2 viral strains.
此項獎勵的資金來自3.2億美元的“NextGen”計劃,這是HHS爲推進一系列新的創新疫苗和治療藥物而啓動的倡議。BARDA正在支持開發新的疫苗、治療和使能技術,以更好地應對當前和未來的SARS-CoV2病毒株的免疫衰退和抵抗。
This project is being funded with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction (OT) number: 75A50123D00005.
該項目使用來自美國衛生與公共服務部戰略準備和響應管理局(ASPR)下的生物醫學高級研究和開發局(BARDA)的聯合交易(OT)編號:75A50123D00005的聯邦資金進行了資助。
About Walgreens
關於沃爾格林 沃爾格林(
Walgreens () is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of "more joyful lives through better health," Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company's pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation's most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.
沃爾格林(Walgreens)是沃爾格林靴子聯盟公司(Walgreens Boots Alliance,Inc.,納斯達克(WBA))的美國零售藥店和美國醫療保健部門的一部分,是一家綜合醫療保健、藥店和零售業的領導者。一直秉承“通過更好的健康實現更加快樂的生活”的宗旨,沃爾格林有超過120年的爲社區服務和提供可靠藥房服務的歷史,今天在作爲獨立的合作伙伴方面扮演着更爲重要的角色,提供有助於改善護理、降低成本並幫助患者的醫療保健服務。在美國及波多黎各境內擁有近9000個零售店鋪,沃爾格林自豪地爲近900萬客戶和患者提供服務。該公司的藥劑師扮演着比以往任何時候都更爲重要的醫療保健角色,提供廣泛的藥房和醫療保健服務,包括推動爲一些國家最貧困的人群實現公平護理所需的服務。沃爾格林爲客戶和患者提供真正的全渠道體驗,擁有完全集成的實體和數字平台,旨在提供高質量的產品和醫療保健服務。在美國醫療保健部門內,沃爾格林的組合還包括初級保健、多科專業、後急診護理、特別藥房服務、人口健康和提供商啓用業務。
Media Contact
媒體聯繫人
Carmen Lopez
media@walgreens.com
卡門·洛佩茲
media@walgreens.com